THOUSAND OAKS, Calif., - November 5, 2002 - Amgen (Nasdaq:AMGN) announced that its Business Review Meeting will be held on February 25, 2003 in Los Angeles. Amgen will provide 2003 financial guidance on an investor conference call on December 12, 2002. Details for this conference call will be communicated in the near future.
The Business Review Meeting had been scheduled for November 21, 2002 and has been rescheduled to provide a clearer long-term picture of Amgen, and to allow the Company to better address several near term issues. The issues include, but are not limited to, the re-launch of ENBREL® and its increased supply, a decision on the TKT legal appeal, and the progress of Amgen's efforts to correct inaccuracies released in the CMS OPPS rule.
Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.
Contact: Amgen, Thousand Oaks
Jeff Richardson, 805/447-3227 (media)
Cary Rosansky, 805/447-4634 (investors)
EDITOR'S NOTES: An electronic version of this news release may be accessed via our web site at http://www.amgen.com. Visit the Corporate Center and click on Amgen News. Journalists and media representatives may sign up to receive all news releases electronically at time of announcement by filling out a short form in the Amgen News section of the web site.